GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citi Pharma Ltd (KAR:CPHL) » Definitions » Price-to-Owner-Earnings

Citi Pharma (KAR:CPHL) Price-to-Owner-Earnings : (As of May. 10, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Citi Pharma Price-to-Owner-Earnings?

As of today (2025-05-10), Citi Pharma's share price is ₨64.66. Citi Pharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Citi Pharma's Price-to-Owner-Earnings or its related term are showing as below:


KAR:CPHL's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 24.05
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-10), Citi Pharma's share price is ₨64.66. Citi Pharma does not have enough years/quarters to calculate the Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in . 20. Therefore GuruFocus does not calculate PE Ratio (TTM) at this moment.

As of today (2025-05-10), Citi Pharma's share price is ₨64.66. Citi Pharma does not have enough years/quarters to calculate the EPS without NRI for the trailing twelve months (TTM) ended in . 20. Therefore GuruFocus does not calculate PE Ratio without NRI at this moment.


Citi Pharma Price-to-Owner-Earnings Historical Data

The historical data trend for Citi Pharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citi Pharma Price-to-Owner-Earnings Chart

Citi Pharma Annual Data
Trend
Price-to-Owner-Earnings

Citi Pharma Semi-Annual Data
Price-to-Owner-Earnings

Competitive Comparison of Citi Pharma's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Citi Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Citi Pharma's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citi Pharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Citi Pharma's Price-to-Owner-Earnings falls into.


;
;

Citi Pharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Citi Pharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=64.66/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Citi Pharma  (KAR:CPHL) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Citi Pharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Citi Pharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Citi Pharma Business Description

Traded in Other Exchanges
N/A
Address
588 Q Block, Johar Town, Lahore, PB, PAK
Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its departments include Active Pharma Ingredients (API) and Formulations. Some of its products include Askprol C Tab, Lenon Tab, Recoz Tab, Cingol Tab among others.

Citi Pharma Headlines

No Headlines